Show simple item record

dc.contributor.authorJie, Zhenwang
dc.contributor.authorZhang, Yu
dc.contributor.authorWang, Chen
dc.contributor.authorShen, Bin
dc.contributor.authorGuan, Xin
dc.contributor.authorRen, Zhihua
dc.contributor.authorDing, Xinxin
dc.contributor.authorDai, Wei
dc.contributor.authorJiang, Yongping
dc.creator
dc.date.accessioned2017-07-14T13:50:23Z
dc.date.available2017-07-14T13:50:23Z
dc.date.issued2017-07-11
dc.identifier.citationJie, Z., Zhang, Y., Wang, C., Shen, B., Guan, X., Ren, Z., . . . Jiang, Y. (2017). Largescale ex vivo generation of human neutrophils from cord blood CD34+ cells. PLoS ONE, 12(7), 1-18. doi:10.1371/journal.pone.0180832en_US
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/1951/69325
dc.description.abstractConventional high-dose chemotherapy frequently leads to severe neutropenia, during which patients experience a high risk of infection. Although support care with donor’s neutrophils is possible this choice is largely hampered by the limited availability of matched donors. To overcome this problem, we explored a large-scale ex vivo production of neutrophils from hematopoietic stem cells (HSCs) using a four-stage culture approach in a roller-bottle production platform. We expanded CD34+ HSCs isolated from umbilical cord blood (UCB) using our in-house special medium supplemented with cytokine cocktails and achieved about 49000-fold expansion of cells, among which about 61% were differentiated mature neutrophils. Ex vivo differentiated neutrophils exhibited a chemotactic activity similar to those from healthy donors and were capable of killing E. coli in vitro. The expansion yield as reported herein was at least 5 times higher than any other methods reported in the literature. Moreover, the cost of our modified medium was only a small fraction (<1/60) of the StemSpan™ SFEM. Therefore, our ex vivo expansion platform, coupled with a low cost of stem cell culture due to the use of a modified medium, makes large-scale manufacturing neutrophils possible, which should be able to greatly ameliorate neutrophil shortage for transfusion in the clinic.en_US
dc.description.sponsorshipState Scientific Key Projects for New Drug Research and Development (2014ZX09101042-004 and 2011ZX09401-027), China International Cooperation and Exchange Program (2013DFA30830), China Biopharmaceutical R&D Center, Peking Union Medical College of Tsinghua University, Suzhou, China Biopharmagen Corporation, Suzhou, China College of Nanoscale Science and Engineering, SUNY Polytechnic Institute, Albany, New York, USA NYU Langone Medical Center, Tuxedo, New York, USAen_US
dc.language.isoen_USen_US
dc.publisherPLoS ONEen_US
dc.subjectantigensen_US
dc.subjectCD34+en_US
dc.subjectcell differentiationen_US
dc.subjectfetal blooden_US
dc.subjecthematopoietic stem cells (HSCs)en_US
dc.subjectneutrophilsen_US
dc.subjectumbilical cord blood (UCB)en_US
dc.subjectneutropeniaen_US
dc.titleLarge-scale ex vivo generation of human neutrophils from cord blood CD34+ cellsen_US
dc.title.alternativePLoS ONEen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record